TABLE 2.
Procedural complications and 30-day clinical outcomes after TAVR.
| Total | Class 1 | Class 2 | Class 3 | P-value | |
| N = 798 | N = 661 | N = 102 | N = 35 | ||
| Procedural complications | |||||
| New or aggravated AV block (%) | 147 (18.42) | 126 (19.06) | 12 (11.76) | 9 (25.71) | 0.11 |
| Vascular complications (%) | 49 (6.14) | 40 (6.05) | 8 (7.84) | 1 (2.86) | 0.57 |
| Annular rupture (%) | 1 (0.13) | 1 (0.15) | 0 (0.00) | 0 (0.00) | 0.99 |
| Coronary obstruction (%) | 7 (0.88) | 6 (0.91) | 1 (0.98) | 0 (0.00) | 0.99 |
| Circulation collapse (%) | 27 (3.38) | 16 (2.42) | 6 (5.88) | 5 (14.29) | <0.01 |
| AR paravalvular ≥ moderate (%) | 50 (6.27) | 36 (5.45) | 11 (10.78) | 3 (8.57) | <0.01 |
| AR transvalvular ≥ moderate (%) | 5 (0.63) | 3 (0.45) | 1 (0.98) | 1 (2.86) | 0.2 |
| Within 30-day post-TAVR outcomes | |||||
| NYHA ≥ Class III (%) | 173 (21.68) | 132 (19.97) | 26 (25.49) | 15 (42.86) | <0.01 |
| Myocardial infarction (%) | 1 (0.13) | 1 (0.15) | 0 (0.00) | 0 (0.00) | 0.99 |
| Stroke (%) | 4 (0.50) | 3 (0.45) | 1 (0.98) | 0 (0.00) | 0.53 |
| Disabling stroke (%) | 3 (0.38) | 2 (0.30) | 1 (0.98) | 0 (0.00) | 0.43 |
| Bleeding (%) | 14 (1.75) | 14 (2.12) | 0 (0.00) | 0 (0.00) | 0.39 |
| Life threatening bleeding (%) | 2 (0.25) | 2 (0.30) | 0 (0.00) | 0 (0.00) | 0.99 |
| New permanent pacemaker (%) | 15 (1.88) | 15 (2.27) | 0 (0.00) | 0 (0.00) | 0.34 |
| New atrial fibrillation (%) | 10 (1.25) | 6 (0.91) | 4 (3.92) | 0 (0.00) | 0.05 |
| Renal dysfunction (%) | 2 (0.25) | 1 (0.15) | 0 (0.00) | 1 (2.86) | 0.1 |
AR, aortic regurgitation; AV, atrioventricular; N, number; NYHA, New York Heart Association; TAVR, transcatheter aortic valve replacement. Circulatory collapse was defined as a patient being in a status with mean arterial pressure ≤65 mmHg or receiving vasopressors.